Professor S. Louise Cosby (SLC) was appointed as Head of Virology Branch at the Agri-Food and Biosciences institute, UK, in 2015. She was Chair of Microbiology in Queen’s University Belfast from 2002 and remains an emeritus professor. SLC is a Fellow of Royal College of Pathologists (London) and Fellow of the Royal Society of Biology, UK. She has served/currently serves on grant/editorial boards: BBSRC, UK; Chair/member, Science Foundation Ireland; Deputy Chair Professional Development Committee, Microbiology Society, UK; Associate Editor, Journal of Neurovirology, USA; Review editor, Frontiers in Microbiology; External Assessor for Appointments and Promotions in Medical Microbiology, University of Malaysia. Research interests: in virus pathogenesis including virus-receptor interactions, virus-induced immunosuppression as well as novel diagnostics and vaccine development. Work has focused on paramyxoviruses of both human and veterinary interest, with publications/grant funding in this area.
Measles vaccination: Threat from related veterinary viruses and need for continued vaccination post measles eradication
Dr. Jun Dou now is a Director, Professor of Department of Pathogenic Biology and Immunology, School of Medicine, Southeast University. He got his Medicine Doctor degree (MD, PhD) in 1997 at Zhejiang University of China. Dr. Jun Dou visited the Ulm University School of Medicine, Germany as a Visiting Scholar from Jun 1999 to Sept.1999, and then visited the CDC, USA as a senior visiting fellow from Oct. 2001 to Feb.2004. And Dr. Jun Dou visited the Georgia State University, USA as a visiting fellow from Sept. 2006 to Dec. 2006. Recently, Dr. Dou visited the Yale University School of Medicine, USA twice as a senior visiting fellow in 2014 and in 2015. Currently Dr. Dou’s research has focused on the cancer stem cells (CSCs), the targeted CSCs by manipulation of nc-RNAs to treat breast, ovarian, colon cancers, and melanoma, as well as the CSC vaccines and CSC nanotheranostics.
Colon cancer stem cell-based vaccine reduces efficiently both Tumor growth and cancer stem cell subpopulation in a mouse colon carcinoma model
For more than 25 years Dr. Fattom led research in vaccine discovery and development against infectious diseases and addiction. After a 5 years tenure in vaccine research at the NIH, under Dr. John Robbins, Dr. Fattom moved to the biotech industry, he joined Nabi Biopharmaceuticals, to lead bacterial vaccines development. His work on Staphylococcus aureus pathogenesis, determination of virulence factors, and identifying protective antigens for developing a protective vaccine against this pathogen are well recognized in the field. Nicotine vaccine, a second lead vaccine developed by Dr. Fattom for smoking cessation was also developed through phase II clinical trials. In 2010, Dr. Fattom joined NanoBio Corp. as a Sr. VP of vaccine research and development. For the last 6 years, his efforts were focused on developing intranasal vaccines against respiratory (Flu, RSV, Anthrax, and Pertussis), and sexually transmitted diseases (Genital herpes HSV2, Chlamydia, and HIV). Target indication for these vaccines is to protect against disease, carriage, shedding/transmission. Dr. Fattom holds an Adjunct professor at the University of Michigan since 2012. He authored >70 publications and >20 issued patents. He is a reviewer for NIAID and NIDA grant applications and a reviewer for several journals including Vaccine, Infection and Immunity, Human Vaccines & Immunotherapeutics, and NPJ Vaccine.
Can mucosal immunity succeed where other systemic immune responses failed? Intranasal immunization using a NanostatTM platform technology protected against respiratory and sexually transmitted diseases in the appropriate animal challenge models
Dr. M. Tary-Lehmann is a Co-Founding Scientist and Chief Scientific Officer for Cellular Technology Limited (CTL) and an Adjunct Associate Professor of Case Western Reserve University (CASE) Department of Pathology. She has published more than 75 papers in peer-reviewed journals. She provides guidance and oversees technical operations of the performance of immunology assays in CTL’s GLP- and CLIA compliant contract laboratory for various pharmaceutical and biotechnology clients, ensuring the ongoing scientific excellence of CTL. Over the past decade, she has worked with clients and regulatory agencies to develop and validate reference samples and controls for use in regulated immune monitoring assays.
Feasibility of Monitoring Cell Mediated Immunity during Vaccine Trials
Giulio Tarro graduated from Medicine School, Naples University (1962), Italy. Research Associate, Division of Virology and Cancer Research, Children’s Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. Oncological Virology Professor, Naples University (1972-1985). Chief Division Virology (1973-2003), Head Department Diagnostic Laboratories, (2003-2006). D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus (2006). Since 2007 Chairman Committee of Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization lifetime achievement award (2010). President, Foundation de Beaumont Bonelli for Cancer Research. His basic researches have been concerned with antigens induced early during the replication cycle of human herpesviruses. Another study has involved the identification, isolation, and characterization of specific virus-induced tumor antigens, which were the "fingerprints" left behind in human cancer. Achievements include patents in a field; a discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor-associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas.
Tumor liberated protein (TLP) as potential vaccine for lung cancer patients
Dr. Ogra’s career in medicine began in the early 1960’s. His academic leadership has focused on research, teaching and patient care in childhood infections, mucosal vaccine development, and definition of biologic markers of immunity against human infections. His major scientific contributions began with the first functional characterization of secretory IgA and “alimentary” mucosal immunity in natural or vaccine induced infection with poliovirus. In subsequent investigations, he defined the role of secretory IgA and cellular mucosal immune responses to such human infections as rubella, mumps, hepatitis B virus and enteroviruses. His laboratory provided extensive immunologic characterization of human milk, its role in maternal-neonatal interactions and childhood infections, and the association of mammary glands with other components of the common mucosal immune system. Other investigations from his laboratory identified important components of host-pathogen interactions underlying the pathogenesis of mucosal infections, notably in Bronchiolitis due to respiratory syncytial virus (RSV), gastroenteritis due to rotavirus, and immunologic aspects of Otitis media in childhood. These include, demonstration of RSV specific IgE in the respiratory mucosa and its role in viral induced reactive airway disease, identification of rotavirus- specific receptor-binding sites in villous enterocytes in early infancy and the role of Bifidobacteria in modulating rotavirus-mucosal cell interactions, and development of IgA and other aspects of mucosal immune responses in the middle ear mucosa during otitis media. Dr. Ogra served as the chief of Pediatric infectious diseases and Professor of Pediatrics and Microbiology at the University at Buffalo, State University of New York until 1990, when he was appointed as the John Sealy Distinguished Chair Professor and Chairman of the Department of Pediatrics at the University of Texas Medical Branch (UTMB), Pediatrician-in-Chief at the UTMB Children's Hospital, and as Professor of Microbiology and Immunology.. He retired from this position in 2002. Since that time, he has returned to the Children’s Hospital of Buffalo and is currently serving as Professor Emeritus, Department of Pediatrics at the State University of New York at Buffalo. Dr. Ogra has been a member of over 30 prestigious national and international scientific societies, These include election as ; Member, Association of American Physicians, American Society for Clinical Investigation, American Pediatric Society; Fellow ; Royal Society (Medicine) , London, UK . Infectious Diseases Society of America, American Academy of Microbiology. He has received multiple honors and awards, and has served as an honored guest and commencement speaker at medical school graduation events. He has served on many study sections, and national and international advisory panels of World Health Organization, National Institutes of Health (US) Institute of Medicine:, US National academy of Sciences, Federal Drug Administration ,International Vaccine Institute, Seoul, S. Korea, European Union ,Mucosal Vaccine Development Program (MUVAPRED). To date, Dr. Ogra has contributed over 440 peer reviewed original scientific publications and review articles. He has edited, in collaborations with many of his colleagues, 20 full-length books and monographs, has served as the founding editor of the first comprehensive textbook of Mucosal Immunology. During his investigative career, Dr. Ogra has served as the mentor of over 75 post-doctoral fellows and PhD students in Microbiology and Immunology and training of over 500 Pediatric residents. He continues to remain very active as a consultant and a teacher in the diverse areas of vaccine research and development and in the global issues of childhood infectious diseases. He devotes significant amount of his effort in the field in South Asia, towards the control of vaccine preventable diseases of the poor.
Recent progress in Human mucosal vaccine development: Role of Mucosal Immunity and Mucosal Microbiome in the outcome of vaccine effectiveness
Dr. Ricardo Bordinhão received his Bachelor degree in Pharmacy from the Universidade do Grande Rio - Unigranrio in 2001 and is currently obtaining a degree in Logistics Management & Pharmaceutical Distribution from the Institute of Science, Technology and Quality - ICTQ. He has worked in the pharmaceutical department of a number of renowned hospitals in Rio de Janeiro, developing great expertise in integration and consultancy for ANVISA regulatory matters. He is a member of the Ethics Committee and of the Technical Chamber for Pharmaceutical Logistics of the Regional Pharmacy Council of Rio de Janeiro. He currently works at BRL - DISTRIBUIDORA DE VACINAS LTDA, a Pharmaceutical and Drug distributor where he holds the position of Logistics Manager and Head Pharmacy Technician.
Maely Peçanha Favero-Retto is Graduated in Pharmacy from the Federal University of Rio de Janeiro (1995), Master in Biological Chemistry from UFRJ (1999) and PhD in Pharmaceutical Sciences from UFRJ (2013). Specialist in Hospital Pharmacy (2007) and Clinical Pharmacy (2015) by SBRAFH, with Executive MBA by the COPPEAD Institute (2008). He is currently a Technologist in Hospital Pharmacy at the National Cancer Institute and at the Hospital Municipal Miguel Couto. Professor of the Multiprofessional Residency in Oncology at INCA and postgraduate courses. President of the Brazilian Society of Hospital Pharmacy and Health Services (SBRAFH). Has experience in the field of biological metrology with emphasis on the study of biosimilar products.
Dr. Chil-Yong (Yong) Kang received his Ph.D. from McMaster University in Canada in 1971 and his D.Sc. degrees from McMaster University and from Carleton University. He took his three year postdoctoral training at the University of Wisconsin, Madison, USA. He has served as a Professor of Microbiology at the University of Texas, Southwestern Medical School in Dallas, Professor and Chairman of the Department of Microbiology and Immunology at University of Ottawa, Faculty of Medicine, Dean of Science at the University of Western Ontario, and currently is serving as Professor of Virology in the Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry at the University of Western Ontario. His research in molecular virology includes the development of antiviral therapeutic agents and efficacious vaccines against various human viral diseases. He has published 297 scientific papers in fields of virology, medicine, and molecular biology. He holds nine international patents. Dr. Kang has received numerous prizes including Ho-Am Prize in Medicine in 1999 and Queen Elizabeth II Diamond Jubilee Medal of the Governor General of Canada in 2012. Dr. Kang is an elected Life-time Fellow of the Royal Society of Canada, Academy of Science and an elected Life-time Member of the Korean Academy of Science and Technology.
Félix Fernández Madrid is a Professor of Internal Medicine at Wayne State University in Detroit Michigan. His affiliations are Department of Internal Medicine,Center for Molecular Medicine and Genetics, Karmanos Cancer Institute. Based on the established role of autoantibodies as diagnostic and prognostic biomarkers in the rheumatic autoimmune diseases [RADs] and on their involvement in disease pathogenesis I became interested on a novel biomarker discovery approach which may contribute to the diagnosis of BC and other solid tumors. We demonstrated that autoantibodies in BC are not epiphenomena and that anti-mitochondrial antibodies targeting subunits of mitochondrial electron transfer chain complexes I, IV and V encoded by mtDNA are BC autoantigens, suggesting that these autoantibodies are the expression of mitochondrial autoimmunity in BC. There are established links between chronic inflammation and cancer and autoimmune tissue damage is an accepted concept in the pathogenesis of RADs. A major goal of my research program is to establish the role of tissue damage produced by autoimmunity to breast antigens as contributors to creating a chronic inflammatory milieu promoting the progression of BC, and other solid tumors.
Autoimmunity in Breast Carcinogenesis. Implications for Vaccination in Solid Tumors